share_log

恒瑞医药(600276.SH):HRS-6768注射液获得药物临床试验批准通知书

Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-6768 injection has received the clinical trial approval notification.

Gelonghui Finance ·  Jan 3 02:42

On January 3rd, Gelonghui reported that Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary Tianjin Hengrui Pharmaceuticals Co., Ltd. received the approval notice for the clinical trial of HRS-6768 injection issued by the National Medical Products Administration. Clinical trials will be conducted in the near future. HRS-6768 injection is a Class 1 Innovative Drug for radioactive therapy independently developed by the company, and no similar products have been approved for marketing either domestically or internationally. This product is suitable for patients with advanced solid tumors who are positive for fibroblast activation protein.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment